IgA dominates the early neutralizing antibody response to SARS-CoV-2.

In the subset of patients monitored at the very early time points after disease onset (first 7 days post-symptoms, n = 48), anti-RBD IgA and IgG were detected in 15 and 7 samples, respectively, at concentrations that did not reach statistical significance (positive samples: 31% IgA versus 15% IgG, P = 0.052; calculated from data presented in Fig. 2, A and B , and fig.

also in 111,027 other papers